|
Aftercare of Childhood Cancer Survivors in Switzerland
RECRUITINGSponsored by Kantonsspital Aarau
Actively Recruiting
SponsorKantonsspital Aarau
Started2019-02-12
Est. completion2025-04
Eligibility
Age16 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT04284189
Summary
The Aftercare of Childhood Cancer Survivors in Switzerland (ACCS) study is a multicenter cohort study designed to investigate transition of follow-up care from pediatric oncology to adult care in a prospective and longitudinal way. The investigators collect data on preferences and expectations for follow-up care and transition to adult care by questionnaires in adolescent and young adult survivors of childhood cancer.
Eligibility
Age: 16 Years+Healthy volunteers accepted
Inclusion Criteria: * 5-year survivor of childhood cancer * Diagnosis according to ICCC3 I-XII; Langerhans cell histiocytosis (LCH), Hemophagocytic lymphohistiocytosis (HLH) * Age at diagnosis \<18 years * Age at study ≥16 years * At study start in follow-up care at one of the three pediatric oncology centers (group before transition) or transitioned not before 2014 (group after transition). * Written informed consent Exclusion Criteria: * Treatment only by means of surgery and without increased risk of late effects (e.g. teratoma) * \<5 years after therapy of a relapse or palliative situation * Severe cognitive impairment, which makes it impossible to complete the questionnaire independently * Insufficient knowledge of the German language * Informed consent form not signed
Conditions4
CancerChildhood CancerSurvivorshipTransition
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorKantonsspital Aarau
Started2019-02-12
Est. completion2025-04
Eligibility
Age16 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT04284189